Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs LMB 100 (Primary) ; Pembrolizumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 04 Dec 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 12 Nov 2018 to 10 Dec 2018.
- 08 Nov 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 8 Nov 2018 to 12 Nov 2018.
- 08 Nov 2018 Status changed from not yet recruiting to recruiting.